Print Email

About Study Groups  |  Study Groups  |  Workshops  |  Surveys  |  Resources

MASCC Hemostasis Study Group

Leadership

Chair: Carmen Escalante, MD (cescalan@mdanderson.org) - USA
Vice-Chair: Thomas Butler, MD (tbutler@health.southalabama.edu) - USA
Vice-Chair: Carme Font, MD (cfont@clinic.ub.es) - Spain

Study Group Minutes
2016 Minutes  - Annual Meeting - Adelaide, Australia

Mission and Goals

The mission of the Hemostasis Study Group is to provide guidance and guidelines to healthcare providers regarding bleeding and clotting complications in cancer patients from diagnosis to the end of life. The goals of the group are (1) an increased awareness of abnormalities in the coagulation system at the time of cancer diagnosis, through treatment, and at the end of life, and (2) an increased availability of evidence-based treatment to patients with bleeding or clotting complications during treatment and at the end of life. To these ends, the Group has set the following objectives:

  • To keep up to date with current guidelines regarding treating cancer patients with bleeding and clotting problems related to their disease;
  • To evaluate current guidelines for their merit and deficiencies in providing adequate treatment to cancer patients with coagulation problems;
  • To focus on anticoagulation treatment and quality of life in cancer patients in both hospital and hospice settings.

Research Highlights

The Clinical Course of Venous Thromboembolism May Differ With Cancer Site
Carme Font is one of a large group of investigators who have collaborated on a study of differences in the clinical course of venous thromboembolism (VTE) in relation to specific cancer sites. The study included data from almost 4000 adult patients with active cancer. Significant differences in the clinical profile of VTE-related outcomes were associated with tumor location. The findings suggest that individualized anticoagulation strategies for cancer-related VTE could improve outcomes and quality of life, while reducing treatment costs. >> Read more.

Incidental Venous Thromboembolism in Cancer Patients on Routine CT Scans
In a prospective cohort study, Carmen Escalante et al. investigated the prevalence of incidental venous thromboemtolism (VTE) in almost 1100 adult cancer patients on routine staging CT scans of the chest, abdomen, or pelvis. The research team also documented symptoms associated with incidental VTEs and determined the incidence of VTE recurrence in these patients after 3 and 6 months. >> Read more.

Romiplostim for the Management of Chemotherapy-Induced Thrombocytopenia
Chemotherapy-induced thrombocytopenia (CIT) can interfere with the optimal course of chemotherapy by necessitating schedule delays and dosage reductions. Some patients experience more severe or persistent thrombocytopenia than others, and their responses are neither well understood nor predictable. Both the prevention and management of CIT are critical in order for patients to benefit fully from chemotherapy. Recently, Dr. Rekha Parameswaran and colleagues reported on the successful use of weekly romiplostim for reducing CIT. Their review included both response to romiplostim therapy and toxicity assessment.  >> Read more

Outpatient Management of Pulmonary Embolism in Cancer
Dr. Carme Font and colleagues in Spain conducted a prospective cohort study to determine the feasibility of outpatient treatment for patients with cancer and sudden, symptomatic vs. incidental PE. They assessed thromboembolism recurrence, major bleeding, and all-cause mortality. The authors also compared the performance of four different prognostic scales in predicting mortality and identifying patients who might be treated at home. The results suggest that a large proportion of patients with cancer and PE can be safely treated as outpatients, particularly those with incidental PE. >> Read more

2017 Workshop

2017 Annual Meeting Workshop, June 22, Washington, DC
Update on Venous Thromboembolism: Approach and Challenges
This workshop will bring together a multinational group of experts to review current evidence and needed knowledge in the area of cancer-associated venous thromboembolism (VTE). It will include discussions of the clinical challenges as well as promote the education of patients, providers, and family members. Highlights include VTE prevention in ambulatory cancer patients, management of long-term treatment, and new oral anticoagulants. The workshop will focus on best practices, as illustrated by case studies, and will include discussion and illustration of various approaches to educating and engaging patients in the treatment process. The workshop will also include a patient presenter, who will speak to the group about the challenges of VTE and quality of life. 

This workshop will be offered jointly by the following MASCC Study Groups: Education; Hemostasis.
Workshop Chairs: Carme Font, Carmen Escalante, Tom Butler, Paz Fernández-Ortega

Recent Member Publications

Recent Study Group member publications related to bleeding and clotting complications in cancer patients.

Webcast

What's New in the Management of Blood Clots for Cancer Patients 
Richard J. Gralla, MD, Rekha Parameswaran, MD, David A. Slosky, MD, Carolyn Messner, DSW, MSW. 
This 2012 webcast on the management of blood clots for cancer patients is available at Cancercare.org. You can view the webcast online or download an MP3 file. Topics include new treatments for venous thromboembolism, clinical trials and treatment options, the role of the FDA, and new clinical management strategies.


Please contact the Study Group Chairs above with your questions.
MASCC Study Group Coordinator, Don Gubitosa